Our lab's first paper received honourable mention for the Zisikind-Somerfeld research award! The award is given annually by the Society of Biological Psychiatry based on quality of the science and the interest it has generated.
The paper, lead by Jessica Tooley: Glutamatergic Ventral Pallidal Neurons Modulate Activity of the Habenula-Tegmental Circuitry and Constrain Reward Seeking was published last year in Biological Psychiatry with a commentary by Darq and Kieffer.
Meaghan Creed received the Rita Allen Foundation Award in Pain.
Deep brain stimulation is a neuromodulation therapy allowing for targeting of neural circuits, and has emerged a potential therapy for chronic pain. Chronic pain is comprised of sensory, affective and cognitive symptoms; reward deficiency, which is the decreased responsiveness to rewards and manifesting as negative affect, is a cardinal feature of CP and significantly impairs quality of life for chronic pain patients. To develop rational DBS paradigms, we must first understand how dysfunction of specific neural circuits contributes to specific symptoms of chronic pain, and how this dysfunction is expressed at the molecular and synaptic levels.
Support from the Rita Allen Foundation and American Pain society will allow the Creed Lab team to investigate how prolonged pain experience drives functional changes in the mesolimbic reward system. Ultimately, we hope to use this mechanistic understanding of circuit changes to normalize communication between neurons to restore circuit function and offer novel treatments for the affective symptoms of chronic pain disorders.
The ability to appropriately integrate and respond to rewarding and aversive stimuli is essential for survival. The ventral pallidum (VP) plays a critical role in processing both rewarding and aversive stimuli. However, the VP is a heterogeneous structure, and how VP subpopulations integrate into larger reward networks to ultimately modulate these behaviors is not known. Using neurochemical, genetic, and electrophysiology approaches, we characterized glutamatergic VP neurons. Glutamatergic VP neurons exhibit little overlap with cholinergic or gamma-aminobutyric acidergic markers, the canonical VP subtypes, and exhibit distinct membrane properties. Glutamatergic VP neurons innervate and increase firing activity of the lateral habenula, rostromedial tegmental nucleus, and gamma-aminobutyric acidergic ventral tegmental area neurons. While nonselective optogenetic stimulation of the VP induced a robust place preference, selective activation of glutamatergic VP neurons induced a place avoidance. Viral ablation of glutamatergic VP neurons increased reward responding and abolished taste aversion to sucrose. These data support a model in which a glutamatergic VP neurons adaptively constrain reward seeking in the face of aversive stimuli, by modulating habenula and tegmental circuitry.
In the April, 2019 issue of Current Opinion in Neurobiology, read about neuromodulation interventions being applied for substance use disorders, and how pre-clinical studies of circuit function can inform novel therapies. The highlights:
• Clinical studies support the use of STN-DBS and NAc-DBS for treating addiction.
• Pre-clinical studies can inform DBS parameters by elucidating underlying mechanisms.
• Novel paradigms normalize circuit function to reduce behavioral symptoms of addiction.
• New targets, frequencies and technologies are promising avenues for optimizing stimulation.